Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
15.83
+0.17 (1.09%)
Sep 18, 2025, 9:53 AM EDT - Market open
Avadel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Avadel Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $20.88, which forecasts a 31.90% increase in the stock price over the next year. The lowest target is $12 and the highest is $36.
Price Target: $20.88 (+31.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avadel Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $36 | Strong Buy | Maintains | $24 → $36 | +127.42% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Initiates $16 | Hold | Initiates | $16 | +1.07% | Sep 3, 2025 |
| UBS | UBS | Strong Buy Maintains $13 → $20 | Strong Buy | Maintains | $13 → $20 | +26.34% | Aug 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +51.61% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +38.98% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
278.30M
from 169.12M
Increased by 64.56%
Revenue Next Year
363.47M
from 278.30M
Increased by 30.60%
EPS This Year
0.24
from -0.51
EPS Next Year
0.81
from 0.24
Increased by 234.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 288.6M | 397.2M | |||
| Avg | 278.3M | 363.5M | |||
| Low | 264.8M | 327.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 70.7% | 42.7% | |||
| Avg | 64.6% | 30.6% | |||
| Low | 56.6% | 17.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.36 | 1.30 | |
| Avg | 0.24 | 0.81 | |
| Low | 0.17 | 0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 438.3% | |
| Avg | - | 234.3% | |
| Low | - | 98.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.